Perfuze’s Milliped 088 Clot Aspiration Catheter Approved in Europe

May 4, 2021—Perfuze Limited announced that the first five acute ischemic stroke patients have been treated with the company’s Millipede 088 clot aspiration catheter, which received CE Mark approval in February 2021.

According to the company, which is based in Galway, Ireland, the Millipede device has a 0.088-inch inner diameter that provides increased distal tip surface area and aspiration power and distal flow control that may prevent distal emboli.

John Thornton, MB BCh, an interventional neuroradiologist at Beaumont Hospital in Dublin, Ireland, performed the first case with the device.

“Our initial experience with the device has been very positive, I believe the large bore and distal flow control capability offers unique safety and efficacy advantages over existing devices,” commented Dr. Thornton in Perfuze’s press release.

Matt Crockett, MCh, who is an interventional neuroradiologist at Beaumont Hospital, added, “I am extremely pleased with the device. In the thrombectomy case that I performed, the Millipede 088 was used as primary therapy for the patient. It ingested a large occlusive M1 clot in a single pass, resulting in a mTICI 3 reperfusion (complete vessel re-opening) in less than 15 minutes.”

The company advised that the Millipede has not been approved by the FDA and is not commercially available in the United States. In 2019, Perfuze received Breakthrough Device designation from the FDA in recognition of the Millipede’s potential to provide for more effective treatment of a life-threatening disease.